209 related articles for article (PubMed ID: 30409980)
1. FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis.
van Golen RF; Olthof PB; Lionarons DA; Reiniers MJ; Alles LK; Uz Z; de Haan L; Ergin B; de Waart DR; Maas A; Verheij J; Jansen PL; Damink SWO; Schaap FG; van Gulik TM; Heger M
Sci Rep; 2018 Nov; 8(1):16529. PubMed ID: 30409980
[TBL] [Abstract][Full Text] [Related]
2. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
3. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
4. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
[TBL] [Abstract][Full Text] [Related]
5. miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis.
Balasubramaniyan N; Devereaux MW; Orlicky DJ; Sokol RJ; Suchy FJ
J Biol Chem; 2021 Dec; 297(6):101400. PubMed ID: 34774795
[TBL] [Abstract][Full Text] [Related]
6. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia.
Pataia V; McIlvride S; Papacleovoulou G; Ovadia C; McDonald JAK; Wahlström A; Jansen E; Adorini L; Shapiro D; Marchesi JR; Marschall HU; Williamson C
Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G197-G211. PubMed ID: 32597707
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
10. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
11. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
13. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
14. Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction.
Yan M; Hou L; Cai Y; Wang H; Ma Y; Geng Q; Jiang W; Tang W
Front Pharmacol; 2022; 13():906452. PubMed ID: 35770078
[No Abstract] [Full Text] [Related]
15. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury.
Lu Q; Zhu Y; Wang C; Zhang R; Miao Y; Chai Y; Jiang Z; Yu Q
Life Sci; 2024 Jan; 337():122355. PubMed ID: 38104861
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
19. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
[TBL] [Abstract][Full Text] [Related]
20. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
Wagner M; Fickert P; Zollner G; Fuchsbichler A; Silbert D; Tsybrovskyy O; Zatloukal K; Guo GL; Schuetz JD; Gonzalez FJ; Marschall HU; Denk H; Trauner M
Gastroenterology; 2003 Sep; 125(3):825-38. PubMed ID: 12949728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]